Response predictors to treatment with pegylated interferon in chronic hepatitis B
AUTOR(ES)
Ferreira, Paulo Roberto Abrão, Tenore, Simone de Barros
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2010-10
RESUMO
The clinical and epidemiological importance of chronic B hepatitis is currently unquestionable as a cause of end-stage liver disease and hepatocellular carcinoma. Recently, predictors of treatment response of this disease have been studied, both before and during the course of medication. Therapy stopping rules have been proposed, which may be useful in patients presenting poor treatment tolerance. This review discusses the treatment response predictors usefulness, with emphasis on ALT, quantitative HBsAg and HBeAg, quantitative HBV-DNA and HBV genotype
Documentos Relacionados
- Expectoration of large bronchial casts secondary to the treatment of chronic hepatitis c with pegylated interferon and ribavirin
- The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients
- DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN
- Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil
- Dilated cardiomyopathy and hypothyroidism associated with pegylated interferon and ribavirin treatment for chronic hepatitis C: case report and literature review
